Sangamo Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regul ...
Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...